In a monumental stride toward medical advancement, regulatory authorities in the United States have granted approval for two gene therapies intended to combat sickle cell disease—a painful, hereditary blood disorder that predominantly affects Black individuals in the country.

The Food and Drug Administration (FDA) announced on Friday its authorization of these one-time treatments designed for patients aged 12 and above grappling with severe manifestations of the illness. Notably, one of the approved therapies, developed jointly by Vertex Pharmaceuticals and CRISPR Therapeutics, marks a significant milestone as the inaugural therapy sanctioned utilizing CRISPR, the groundbreaking gene editing tool that earned its creators the Nobel Prize in 2020. The other treatment, developed by Bluebird Bio, operates via a distinct mechanism.

Dr. Nicole Verdun of the FDA expressed, "Sickle cell disease is a rare, debilitating, and life-threatening blood disorder with substantial unmet needs. We are enthusiastic about advancing the field, particularly for individuals whose lives have been severely impacted by the disease." These two gene therapies stand as the inaugural FDA-approved treatments in the U.S. specifically tailored for sickle cell disease, supplementing the 15 gene therapies previously greenlit for other medical conditions.

Within the United States, approximately 100,000 individuals contend with sickle cell disease, with nearly one-fifth of them experiencing the severe form of the condition. Sickle cell disease predominantly affects Black populations, with roughly 1 in every 365 Black babies born nationally carrying the disease. Researchers posit that individuals carrying the sickle cell trait might possess protection against severe malaria, contributing to a higher prevalence in regions prone to mosquitoes, such as Africa, or among individuals whose lineage traces back to these regions.

This ailment wreaks havoc on hemoglobin—the vital protein within red blood cells responsible for oxygen transport. A genetic anomaly prompts the cells to adopt a sickle or crescent shape, impeding blood flow and leading to agonizing pain, organ damage, stroke, and other complications.

Existing treatments encompass medications and blood transfusions, while the sole enduring solution rests in a bone marrow transplant sourced from a closely matched, disease-free donor—yet this procedure carries the risk of rejection.

The newly approved gene therapies eliminate the necessity for a donor by effecting permanent alterations to the DNA within the patient's blood cells. The objective of Vertex's therapy, known as Casgevy, revolves around facilitating the body's return to producing a fetal form of hemoglobin present at birth, as it is the adult form that proves defective in individuals with sickle cell disease. CRISPR technology is employed to disable a gene in stem cells obtained from the patient.

Bluebird's treatment, named Lyfgenia, seeks to introduce modified gene copies that aid in the production of "anti-sickling" hemoglobin within red blood cells, preventing or reversing the aberrant cell shapes.

The FDA's green light for these groundbreaking therapies marks a pivotal moment in the quest for more effective and enduring treatments for sickle cell disease, offering hope and potentially life-altering relief to those grappling with this debilitating condition.

Here's How to Recognize the Hidden Dangers of Repeatedly Using the Same Glass for Drinking Water